*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.
QuidelOrtho's upcoming earnings report on October 29th is set against a backdrop of anticipation, particularly as the market closely watches whether the company can surpass the whisper number of $0.51 EPS, which slightly exceeds the consensus estimate of $0.46. With a market cap of approximately $1.91 billion, QuidelOrtho's performance will be scrutinized for signs of resilience and growth potential, especially in the absence of recent news to guide expectations. The revenue estimate stands at $664.90 million, and meeting or exceeding this figure could reinforce investor confidence in the company's strategic direction and operational efficiency. As the healthcare diagnostics sector continues to evolve, QuidelOrtho's ability to innovate and capture market share will be pivotal, making this earnings release a key moment for stakeholders assessing the company's future trajectory.
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for infectious disease, cardiology, thyroid, general and women's health, eye health, gastrointestinal disease, and toxicology applications globally. The company is headquartered in San Diego, California.
Website: https://www.quidelortho.com
Average Sentiment Score:
Overall Sentiment: